These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 3520045

  • 1. [Prophylaxis of acute graft-versus-host disease after allogeneic bone marrow transplantation--combination protocol of high dose methylprednisolone, prednisolone and methotrexate].
    Shinohara Y, Kai S, Misawa M, Fujimori Y, Okamoto T, Kohsaki M, Kanamaru A, Ifuku H, Ohe Y, Hara H.
    Rinsho Ketsueki; 1986 Jan; 27(1):30-5. PubMed ID: 3520045
    [No Abstract] [Full Text] [Related]

  • 2. Combination of cyclosporine and methotrexate for prophylaxis of acute graft versus host disease after allogeneic bone marrow transplantation for leukaemias.
    Mrsić M, Labar B, Bogdanić V, Nemet D, Pavletić Z, Plavsić F, Dobrić I, Kastelan A, Marusić M, Zupancić-Salek S.
    Bone Marrow Transplant; 1989 Dec; 4 Suppl 3():95-6. PubMed ID: 2697416
    [No Abstract] [Full Text] [Related]

  • 3. [Prophylaxis with FK-506 for graft-versus-host disease after transplantation of bone marrow from unrelated donors].
    Hamazaki T, Yagi K, Inoue M, Sakata N, Okamura T, Yasui M, Sasabe M, Kishimoto T, Inoue A, Kawa K.
    Rinsho Ketsueki; 2000 May; 41(5):430-6. PubMed ID: 10879106
    [Abstract] [Full Text] [Related]

  • 4. Cyclosporine and methylprednisolone for prophylaxis of acute graft-versus-host disease.
    Shepherd JD, Shore TB, Reece DE, Barnett MJ, Klingemann HG, Buskard NA, Phillips GL.
    Bone Marrow Transplant; 1988 Nov; 3(6):553-8. PubMed ID: 3063323
    [Abstract] [Full Text] [Related]

  • 5. Methylprednisolone, cyclosporine and methotrexate for prophylaxis of acute graft-versus-host disease.
    Yau JC, LeMaistre CF, Zagars GK, Williams LA, Meneghetti CM, Luke DR, Dunphy FR, Spinolo JA, Jagannath S, Spitzer G.
    Bone Marrow Transplant; 1990 Apr; 5(4):269-72. PubMed ID: 2337738
    [Abstract] [Full Text] [Related]

  • 6. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation.
    Michallet M, Perrin MC, Belhabri A, Molina L, Nicolini F, Tigaud JD, Sotto JJ, Guyotat D, Fière D, Archimbaud E.
    Bone Marrow Transplant; 1999 Jan; 23(2):145-50. PubMed ID: 10197799
    [Abstract] [Full Text] [Related]

  • 7. Low incidence of acute graft-versus-host disease and recurrent leukaemia in patients undergoing allogeneic haemopoietic stem cell transplantation from sibling donors with methotrexate and dose-monitored cyclosporin A prophylaxis.
    Byrne JL, Stainer C, Hyde H, Miflin G, Haynes AP, Bessell EM, Russell NH.
    Bone Marrow Transplant; 1998 Sep; 22(6):541-5. PubMed ID: 9758340
    [Abstract] [Full Text] [Related]

  • 8. [Comparison study on treatment of acute graft-versus-host disease with low-dose methotrexate in combination with low-dose methylprednisolone or standard-dose methylprednisolone].
    Wang J, Xu LP, Liu DH, Liu KY, Chen H, Chen YH, Han W, Wang Y, Huang XJ.
    Zhonghua Xue Ye Xue Za Zhi; 2011 Aug; 32(8):512-5. PubMed ID: 22338171
    [Abstract] [Full Text] [Related]

  • 9. Graft-versus-host-disease prophylaxis for matched unrelated donor bone marrow transplantation: comparison between cyclosporine-methotrexate and cyclosporine-methotrexate-methylprednisolone.
    Leelasiri A, Greer JP, Stein RS, Goodman S, Brandt SA, Edwards JR, Wolff SN.
    Bone Marrow Transplant; 1995 Mar; 15(3):401-5. PubMed ID: 7599565
    [Abstract] [Full Text] [Related]

  • 10. Acute graft-versus-host disease after allogeneic bone marrow transplantation.
    Perreault C, Gyger M, Boileau J, Bonny Y, Cousineau S, Lacombe M, Lavallee R, Tawil E, D'Angelo G.
    Can Med Assoc J; 1983 Nov 01; 129(9):969-74. PubMed ID: 6367917
    [Abstract] [Full Text] [Related]

  • 11. Continuous infusion cyclosporine and nifedipine to day +100 with short methotrexate and steroids as GVHD prophylaxis in unrelated donor transplants.
    Liesveld J, Duerst R, Rapoport A, Constine L, Abboud C, Packman C, Wedow L, Zwetsch L, McKenna B, Linder T, Silverman W, Swift S, Rowe J, DiPersio J.
    Bone Marrow Transplant; 1999 Sep 01; 24(5):511-6. PubMed ID: 10482935
    [Abstract] [Full Text] [Related]

  • 12. Combination graft-versus-host disease prophylaxis using immunotoxin (anti-CD5-RTA [Xomazyme-CD5]) plus methotrexate and cyclosporine or prednisone after unrelated donor marrow transplantation.
    Weisdorf D, Filipovich A, McGlave P, Ramsay N, Kersey J, Miller W, Blazar B.
    Bone Marrow Transplant; 1993 Nov 01; 12(5):531-6. PubMed ID: 8298565
    [Abstract] [Full Text] [Related]

  • 13. Cyclosporine-A as prevention for graft-versus-host disease in pediatric patients undergoing bone marrow transplants.
    Truog AW, Wozniak SP.
    Oncol Nurs Forum; 1990 Nov 01; 17(1):39-44. PubMed ID: 2405360
    [Abstract] [Full Text] [Related]

  • 14. Cyclosporin A and mini short-term methotrexate vs cyclosporin A as graft-versus-host disease prophylaxis in patients with beta thalassemia major undergoing allogeneic blood and marrow transplantation.
    Iravani M, Mousavi A, Gholibeikian S, Bahar B, Samiee S, Ashouri A, Eghbal L, Ghavamzadeh A.
    Bone Marrow Transplant; 2005 Jun 01; 35(11):1095-9. PubMed ID: 15821773
    [Abstract] [Full Text] [Related]

  • 15. Tacrolimus and methotrexate for the prophylaxis of acute graft-versus-host disease in allogeneic bone marrow transplantation in patients with hematologic malignancies.
    Uberti JP, Silver SM, Adams PT, Jacobson P, Scalzo A, Ratanatharathorn V.
    Bone Marrow Transplant; 1997 Jun 01; 19(12):1233-8. PubMed ID: 9208118
    [Abstract] [Full Text] [Related]

  • 16. Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Ringdén O, Labopin M, Gluckman E, Reiffers J, Vernant JP, Jouet JP, Harrousseau JL, Fiere D, Bacigalupo A, Frassoni F, Gorin NC.
    Bone Marrow Transplant; 1996 Nov 01; 18(5):921-9. PubMed ID: 8932846
    [Abstract] [Full Text] [Related]

  • 17. Omission of day 11 methotrexate does not appear to influence the incidence of moderate to severe acute graft-versus-host disease, chronic graft-versus-host disease, relapse rate or survival after HLA-identical sibling bone marrow transplantation.
    Atkinson K, Downs K.
    Bone Marrow Transplant; 1995 Dec 01; 16(6):755-8. PubMed ID: 8750265
    [Abstract] [Full Text] [Related]

  • 18. Addition of low-dose folinic acid to a methotrexate/cyclosporin A regimen for prevention of acute graft-versus-host disease.
    Russell JA, Woodman RC, Poon MC, Jones AR, Ruether BA.
    Bone Marrow Transplant; 1994 Sep 01; 14(3):397-401. PubMed ID: 7994261
    [Abstract] [Full Text] [Related]

  • 19. Methotrexate vs Cyclosporin A as a single agent for graft-versus-host disease prophylaxis in pediatric patients with hematological malignancies undergoing allogeneic bone marrow transplantation from HLA-identical siblings: a single-center analysis in Japan.
    Koga Y, Nagatoshi Y, Kawano Y, Okamura J.
    Bone Marrow Transplant; 2003 Jul 01; 32(2):171-6. PubMed ID: 12838282
    [Abstract] [Full Text] [Related]

  • 20. Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation.
    Schwinghammer TL, Bloom EJ.
    Clin Pharm; 1993 Oct 01; 12(10):736-61. PubMed ID: 8258255
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.